Newsletter | November 21, 2023

11.21.23 -- Respiratory Viral Infections: The Next Frontier For Antiviral Drug Development


Respiratory Viral Infections: The Next Frontier For Antiviral Drug Development

There is still no approved antiviral therapy for adults with RSV infections. As drug developers, we need to prioritize developing new antiviral therapies for immunocompromised patients.


Complex Molecules, Complex Problems

The support of an experienced CDMO is critical to overcoming complexity when working with a highly potent active pharmaceutical ingredient (HPAPI) and when solving solubility challenges.

Sensitive And Reproducible SPR-Based Concentration Analyses

Surface plasmon resonance (SPR) assays are used across the life cycle of a biopharmaceutical and play an important role in defining a detailed quality profile that is based on desired outcomes.

Custom Solutions For Upstream Bioprocesses

Review opportunities for improvement in upstream processing as well as potential solutions to the challenges associated with current approaches.

Particle Investigation: Going One Step Further Than Just The Identification

Discover examples of visible particle identification and the root cause investigation, along with a discussion of the performance of additional troubleshooting using advanced and innovative technologies.


Nona Biosciences Announces Strategic Collaboration With GeneQuantum Healthcare

Solid Biosciences, IND Clearance By FDA For SGT-003 Duchenne Gene Therapy Candidate

Yeast Cells Can Produce Drugs For Treatment Of Psychotic Disorders

Scientists Discover Key To A Potential Natural Cancer Treatment’s Potency

Pancreatic Cancer Discovery Opens The Door For New Clinical Trial At Wilmot

Xsphera Biosciences And NEX-I Collaborate To Advance Oncology Drug Research

Sana Biotechnology Announces FDA Clearance Of IND Application For SC291

A New Dawn In The Fight Against Tuberculosis

Almirall & Absci Announce AI Drug Discovery Partnership

Aurinia Pharmaceuticals Announces Collab Partner Otsuka Filed NDA For LUPKYNIS

Chemomab Therapeutics Receives FDA Fast Track Designation For CM-101


Solid Form Services

Lab Equipment And Testing Site Matrix


Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.